.png){kind=icon}
.png){kind=icon}
Return
Phase 2 Dose Expansion Trial of OBI-3424, a DNA-Alkylating Prodrug, in Patients with Advanced Solid Tumors Expressing AKR1C3
.png){kind=icon}
OA
AI
A
C
D
H
H
M
A
I
K
D
DOI：10.1093/oncolo/oyag254.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
OBI-3424 is an investigational small molecule prodrug. In a dose-escalation trial, the OBI-3424 recommended phase 2 dose (RP2D) was 12 mg/m2 administered every 21 days. In this phase 2 dose-expansion trial, we evaluated the safety and efficacy of OBI-3424 in pancreatic adenocarcinoma and other solid tumor types (“basket” cohort).
Journal
T
IF:
0
Papers:
188
Citations:
0
Organization
Cited Papers